Redeye makes minor revisions based on the Q4 report. Ortoma surprised with product sales in the quarter. The milestone payments were also higher in the quarter. Given where Ortoma is right now, 2024 will be exciting. We maintain our fair value range while increasing our Base case to SEK18.3 per share.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Ortoma Q4’23 - A very exciting year for Ortoma

© Modular Finance, source Nordic Press Releases